Skip to main content

Tisotumab vedotin Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 3, 2024.

Applies to tisotumab vedotin: intravenous powder for solution.

Warning

Intravenous route (Powder for Solution)

WARNING: OCULAR TOXICITYTisotumab vedotin-tftv caused changes in the corneal epithelium and conjunctiva resulting in changes in vision, including severe vision loss, and corneal ulceration.Conduct an ophthalmic exam at baseline, prior to each dose, and as clinically indicated.Adhere to premedication and required eye care before, during, and after infusion.Withhold tisotumab vedotin-tftv until improvement and resume, reduce the dose, or permanently discontinue, based on severity.

Serious side effects of Tisotumab vedotin

Along with its needed effects, tisotumab vedotin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking tisotumab vedotin:

More common

Less common

Incidence not known

Other side effects of Tisotumab vedotin

Some side effects of tisotumab vedotin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to tisotumab vedotin: intravenous powder for injection.

Hematologic

Very common (10% or more): Hemoglobin decreased (52%), lymphocytes decreased (42%), leukocytes decreased (30%), neutrophils decreased (21%)[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (e.g., myalgia, musculoskeletal discomfort, musculoskeletal pain) (21%), arthralgia (16%), pain in extremity/limb discomfort (13%)[Ref]

Ocular

Very common (10% or more): Conjunctival adverse reactions (e.g., conjunctivitis, conjunctival abrasion, conjunctival erosion, conjunctival hyperemia, conjunctival scar, noninfective conjunctivitis, ocular hyperemia, conjunctival hemorrhage) (37%), dry eye/lacrimation increased (29%), corneal adverse reactions (e.g., keratitis, punctate keratitis, ulcerative keratitis, corneal erosion, corneal scar, keratopathy, corneal bleeding) (21%), periorbital adverse reactions (e.g., blepharitis, meibomianitis, eye pruritus, entropion, trichiasis, chalazion, meibomian gland dysfunction) (16%)[Ref]

Metabolic

Very common (10% or more): Weight loss (10%)[Ref]

Respiratory

Very common (10% or more): Epistaxis (39%)[Ref]

Other

Very common (10% or more): Fatigue/asthenia (50%), pyrexia (16%)[Ref]

Very common (10% or more): Creatinine increased (29%), alanine aminotransferase increased (24%), lactate dehydrogenase increased (22%), urate increased (20%), sodium decreased (20%), glucose decreased (19%), aspartate aminotransferase increased (18%), alkaline phosphatase increased (17%), magnesium decreased (17%), creatinine kinase increased (16%), albumin decreased (16%)[Ref]

General

The most common (25% or greater) adverse reactions, including laboratory abnormalities, were hemoglobin decreased, fatigue, lymphocytes decreased, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival adverse reactions, hemorrhage, leukocytes decreased, creatinine increased, dry eye, prothrombin international normalized ratio increased, activated partial thromboplastin time prolonged, diarrhea, and rash.[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (e.g., neuropathy peripheral, peripheral sensorimotor neuropathy, polyneuropathy, peripheral sensory neuropathy, paresthesia, hypoesthesia, burning sensation, neuralgia, sensory loss, peripheral motor neuropathy, muscular weakness, gait disturbance, hyperesthesia) (39%)[Ref]

Renal

Very common (10% or more): Urinary tract infection (e.g., urinary tract infection, urinary tract infection bacterial, cystitis) (24%)[Ref]

Cardiovascular

Very common (10% or more): Hemorrhage (e.g., vaginal hemorrhage, hematuria, rectal hemorrhage, cystitis hemorrhagic, lower GI hemorrhage, urinary bladder hemorrhage, hematochezia, gingival bleeding, postprocedural hemorrhage, radiation associated with hemorrhage, metrorrhagia, large intestinal hemorrhage, paranasal sinus hemorrhage, hemoptysis (50%)[Ref]

Dermatologic

Very common (10% or more): Alopecia (39%), Rash (e.g., ash, rash maculo-papular, rash macular, dermatitis acneiform, dermatitis allergic, erythema) (25%), pruritus (13%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea/retching (41%), diarrhea/gastroenteritis/colitis (25%), constipation (23%), Abdominal pain (e.g., abdominal pain, abdominal pain upper, abdominal pain lower, abdominal distention, abdominal discomfort) (23%), vomiting (17%)[Ref]

References

1. Product Information. Tivdak (tisotumab vedotin). Seagen Inc. 2021;ORIG-1.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.